Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo.
Although CD8(+) cytotoxic T lymphocytes (CTL) exhibit both Fas ligand (FasL) -based and perforin-based lytic activities, the accepted hallmark of a fully active CTL remains its perforin killing machinery. Yet the origin, rationale for possessing both a slow-acting (FasL) and a fast-acting (perforin) killing mechanism has remained enigmatic. Here we have investigated perforin expression in CTL directly involved in acute tumour (i.e. leukaemias EL4 and L1210) allograft rejection occurring within the peritoneal cavity. We show that at the height of the immune response, the majority of conjugate-forming CD8(+) CTL express high levels of perforin messenger RNA and protein, and kill essentially via perforin. Later however, coinciding with complete rejection, fully cytocidal CTL emerge which exhibit a stark decrease in perforin and now kill preferentially via constitutively expressed FasL. Although late in emergence, and persistent, these powerful CTL are neither effector-memory nor memory CTL. This finding has implications for the monitoring of anti-transplant responses in clinical settings, based on assessing perforin expression in graft infiltrating CD8(+) T cells. The results show that as the immune response progresses in vivo, targeted cellular suicide mainly prunes high perforin-expressing CD8(+) cells, resulting in the gradual switch in effector CTL, from mostly perforin-based to largely Fas/FasL-based killers. Hence, two kinds of CD8(+) CTL have two killing strategies.
Meiraz
Avihai
A
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Garber
Orit Gal
OG
Harari
Shaul
S
Hassin
David
D
Berke
Gideon
G
D000818:Animals; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D053222:Fas Ligand Protein / Q000276:immunology; D006084:Graft Rejection / Q000276:immunology; D007156:Immunologic Memory / Q000276:immunology; D007942:Leukemia, Experimental / Q000276:immunology*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D054353:Perforin / Q000172:deficiency / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D054353:Perforin
Science. 1994 Jul 22;265(5171):528-30
7518614
Mol Immunol. 2003 Jan;39(12):687-95
12531280
Cancer Res. 1973 Dec;33(12):3203-8
4760536
Immunology. 2007 Apr;120(4):502-11
17343612
Annu Rev Cell Dev Biol. 2007;23:495-517
17506701
J Exp Med. 1972 Jun 1;135(6):1334-50
5025438
Blood. 2000 Jul 15;96(2):594-600
10887123
Nat Rev Immunol. 2002 Oct;2(10):735-47
12360212
Annu Rev Immunol. 1991;9:129-57
1910674
Immunology. 1993 Jan;78(1):105-12
8436395
Annu Rev Immunol. 2006;24:321-52
16551252
Cell Death Differ. 2008 Feb;15(2):251-62
17975553
Science. 2003 Nov 7;302(5647):1041-3
14605368
Cell Immunol. 1985 Oct 1;95(1):113-23
3928177
Adv Immunol. 1974;18:67-132
4151339
Int Immunol. 1996 Jan;8(1):57-63
8671589
J Immunol. 1994 Dec 15;153(12):5413-21
7527440
J Immunol. 1994 Sep 15;153(6):2506-14
7521365
Science. 2007 Mar 23;315(5819):1687-91
17332376
Science. 1995 Mar 10;267(5203):1449-56
7533326
J Exp Med. 1993 Jan 1;177(1):195-200
7678113
J Immunol. 1998 Oct 15;161(8):3943-9
9780162
Nat Immunol. 2005 Dec;6(12):1236-44
16273099
Transplant Proc. 1987 Feb;19(1 Pt 1):412-6
3493559
Eur J Immunol. 1999 Oct;29(10):3262-72
10540338
J Immunol. 1988 Sep 1;141(5):1429-36
3261748
Nat Med. 1999 Jan;5(1):90-6
9883845
Cell Death Differ. 2003 Dec;10(12):1320-8
12934063
J Immunol. 1995 Oct 1;155(7):3443-52
7561039
J Immunol. 2007 Aug 15;179(4):2339-48
17675495
Int Immunol. 2002 Jun;14(6):605-13
12039912
J Immunol. 1989 Dec 1;143(11):3440-3
2584700
Cell. 1995 Apr 7;81(1):9-12
7536631
Nat Rev Immunol. 2003 May;3(5):361-70
12766758
Eur J Immunol. 2004 Sep;34(9):2459-70
15307178
Immunol Rev. 2003 Jun;193:58-69
12752671
Transplantation. 1979 Jun;27(6):365-8
111379
Int Immunol. 2001 Apr;13(4):411-9
11282980
Adv Immunol. 2004;83:233-52
15135633
Annu Rev Immunol. 1996;14:207-32
8717513
Immunology. 2002 Mar;105(3):267-77
11918688
Annu Rev Immunol. 2007;25:171-92
17129182
Nature. 1994 May 5;369(6475):31-7
8164737
Nat New Biol. 1973 Apr 25;242(121):237-9
4540806
Immunol Lett. 1998 Feb;60(2-3):89-95
9557949
Cell Immunol. 1975 Jun;17(2):505-16
1125996
J Immunol. 1999 Jun 1;162(11):6312-5
10352241
Annu Rev Immunol. 1994;12:735-73
8011296
J Exp Med. 1972 Dec 1;136(6):1594-604
4641856
Annu Rev Immunol. 2004;22:745-63
15032595
Cell Signal. 2003 Nov;15(11):983-92
14499341
Proc Natl Acad Sci U S A. 1987 Jul;84(14):5004-8
2955414
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10854-8
7526382
Nat Rev Immunol. 2006 Dec;6(12):940-52
17124515
Science. 1972 Aug 4;177(4047):433-4
5043143